Navigation Links
Targeting cancerous vessels

By lowering the level of a neuronal protein, researchers halted the growth of blood vessels that tumors rely on for survival. The findings are reported online in the Journal of Experimental Medicine ( on Jan. 4.

Formerly known for its effects on neuronal growth, the team found that the protein {delta}-catenin is also produced by cells in human blood vessels. By diminishing {delta}-catenin expression, the team disrupted vessel development, or angiogenesis, associated with inflammation in tumors and wounds. As expected, samples of human lung tumors expressed more {delta}-catenin than the surrounding tissues. And normal angiogenesis remained the same regardless of {delta}-catenin.

Because blocking {delta}-catenin stunts only inflammation-induced angiogenesis, the protein may be a promising anti-cancer target, says Charles Lin, an author on the study at Vanderbilt University Medical Center in Tennessee.


Contact: Rita Sullivan
Rockefeller University Press

Page: 1

Related medicine news :

1. Targeting brain cancer cell metabolism may provide new treatment
2. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
3. First live targeting of tumors with RNA-based technology
4. Wistar researchers show targeting normal cells in tumors slows growth
5. Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy's Video-Based Situational Assessments
6. DNA test could be key to targeting treatments for head and neck cancer
7. Another Report Finds Swine Flu Targeting the Young
8. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
9. HIV Atlas Shows Virus Targeting Minorities
10. Targeting tumor behavior may lead to new liver cancer drugs
11. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Post Your Comments:
Related Image:
Targeting cancerous vessels
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: